| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 74026 |
SPDMB CAS:2101206-29-3合成方法 |
86 |
zyl |
2024-12-19 |
| 74027 |
cas:2055041-39-7，Mal-PEG4-Val-Cit-PAB-OH，ADC定制 |
81 |
wyh |
2024-12-19 |
| 74028 |
cas:1347750-81-5，Mal-NH-PEG2-CH2CH2COOPFP ester， ADC试剂 |
78 |
kx |
2024-12-19 |
| 74029 |
金属螯合剂DOTA偶联α-MSH八肽类似物 |
64 |
h |
2024-12-19 |
| 74030 |
cas:1286715-33-0，2,5-Dioxopyrrolidin-1-yl 4-methyl-4-((2-methyl-5-oxo-5-(2-(trimethylsilyl)ethoxy)pentan-2-yl)disulfanyl)pentanoate |
101 |
kx |
2024-12-19 |
| 74031 |
DOTA-conjugated multivalent cyclic-RGD DOTA-共轭多价环RGD肽树枝状大分子 |
69 |
h |
2024-12-19 |
| 74032 |
Azidoethyl-SS-ethylazide CAS:352305-38-5 |
78 |
zyl |
2024-12-19 |
| 74033 |
CAS: 870487-09-5， Boc-Val-Cit-PAB |
78 |
WYQ |
2024-12-19 |
| 74034 |
cas:2101206-67-9，Ald-Ph-amido-PEG1-C2-Pfp ester， ADC试剂 |
71 |
kx |
2024-12-19 |
| 74035 |
Ald-Ph-amido-PEG11-NH-Boc CAS:1245813-70-0 |
94 |
zyl |
2024-12-19 |
| 74036 |
HSA-2-iminothiolane-DOTA HSA-2-亚氨基硫醇-DOTA |
90 |
h |
2024-12-19 |
| 74037 |
cas:1222787-24-7，2,5-Dioxopyrrolidin-1-yl 4-((2-((2-(2-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy)acetamido)ethyl)amino)ethyl)disulfanyl)-4-oxobutanoate |
201 |
kx |
2024-12-19 |
| 74038 |
Tr-PEG5-OH CAS:141282-24-8物理化学性质 |
95 |
zyl |
2024-12-19 |
| 74039 |
CAS: 870487-08-4，Boc-Val-Cit，(S)-2-((S)-2-((叔丁氧基羰基)氨基)-3-甲基丁酰胺基)-5-脲基戊酸 |
95 |
WYQ |
2024-12-19 |
| 74040 |
DOTA-8-Aoc-BBN[7-14]NH |
101 |
h |
2024-12-19 |
| 74041 |
Fmoc-PEG3-Val-Cit，N-Fluorenylmethoxycarbonyl-triethylene glycol-Val-Cit |
81 |
WYQ |
2024-12-19 |
| 74042 |
CAS: 2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP |
78 |
WYQ |
2024-12-19 |
| 74043 |
CAS: 2055024-64-9，Azido-PEG4-Val-Cit-PAB-OH |
80 |
WYQ |
2024-12-19 |
| 74044 |
CAS: 870487-09-5，Boc-Val-Cit-PAB |
84 |
WYQ |
2024-12-19 |
| 74045 |
CAS:784105-33-5 Amino-PEG3-C2-acid的介绍 |
72 |
zyl |
2024-12-19 |
| 74046 |
CAS 863971-53-3：Fmoc-Val-Cit-PAB-PNP |
87 |
WYQ |
2024-12-19 |
| 74047 |
Ald-Ph-amido-PEG11-C2-NH2 CAS:1337889-01-6 |
69 |
zyl |
2024-12-19 |
| 74048 |
cas:2003260-13-5 ， MA-PEG4-Ala-Ala-PAB-PNP，ADC定制 |
72 |
wyh |
2024-12-19 |
| 74049 |
DOTA-NCS-6-Ahx-Phe 19-ST[1-19] DOTA偶联ST肽类似物 |
102 |
h |
2024-12-19 |
| 74050 |
1,4,7,10-四氮杂-n-(1-羧基-3-(4-硝基苯基)丙基)-n,N , N ‴-tris(acetic酸)环十二烷(PA-DOTA) |
67 |
h |
2024-12-19 |
| 74051 |
CAS 159858-22-7：Fmoc-Val-Cit-PAB-OH |
61 |
WYQ |
2024-12-19 |
| 74052 |
cas:5117-19-1，Octanethyl glycol ，八乙二醇的主要特点 |
97 |
zyl |
2024-12-19 |
| 74053 |
CAS 159857-79-1：Val-Cit-PAB-OH，缬氨酸（Val）、琥珀酰亚胺（Cit）和对氨基苯甲酸（PAB）的衍生物 |
100 |
WYQ |
2024-12-19 |
| 74054 |
SPDP-Val-Cit-PAB-OH，ADC定制 |
67 |
wyh |
2024-12-19 |
| 74055 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
93 |
h |
2024-12-19 |
| 74056 |
cas:2054345-67-2，azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
83 |
zyl |
2024-12-19 |
| 74057 |
cas:68617-64-1，SPDP acid，3-(2-吡啶二硫代)丙酸的合成方法 |
118 |
zyl |
2024-12-19 |
| 74058 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
84 |
h |
2024-12-19 |
| 74059 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
89 |
h |
2024-12-19 |
| 74060 |
cas:70539-42-3，EGS Crosslinker，乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
137 |
zyl |
2024-12-19 |
| 74061 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
116 |
h |
2024-12-19 |
| 74062 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
83 |
h |
2024-12-19 |
| 74063 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
74 |
zyl |
2024-12-19 |
| 74064 |
DOTA-AgRP-6E |
110 |
h |
2024-12-19 |
| 74065 |
DOTA-morab-003 DOTA偶联单克隆抗体MORAb-003 |
73 |
h |
2024-12-19 |
| 74066 |
DOTA-Bz-folate DOTA-Bz-叶酸 |
91 |
h |
2024-12-19 |
| 74067 |
cas:55750-53-3，6-Maleimidocaproic acid，6-马来酰亚氨基己酸 |
102 |
zyl |
2024-12-19 |
| 74068 |
cas: Fmoc-PEG3-Val-Cit，ADC定制 |
79 |
wyh |
2024-12-19 |
| 74069 |
钆(III)DOTA-DSPE脂质体 |
77 |
h |
2024-12-19 |
| 74070 |
CAS: 870487-08-4，Boc-Val-Cit，叔丁氧羰基-缬氨酰-L-瓜氨酸 |
70 |
WYQ |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询